Biogen Stock Falls on Alzheimer’s Drug Trial Miss
AI Summary
Biogen's stock has sharply declined following the failure of its Alzheimer's drug trial. This setback raises concerns about the company's future prospects in the biotech sector.
Related Articles
Casal paga por apartamento vendido duas vezes e Justiça manda devolver dinheiro
Globo —
US-Iran draft deal: Proposed framework aims to end hostilities and lift oil sanctions
Egypt Independent —
There’s another COVID refund certain taxpayers could get: Here’s who
Harrisburg Patriot-News —
Malaysia Airlines receives 200th Boeing aircraft with latest Boeing 737-8 delivery
Malay Mail —
Bitcoin rises above $76,500 as Iran deal hopes support risk sentiment
Investing.com —
Hong Kong is the best anchor for Chinese firms seeking global waters
South China Morning Post —